# Plexus Corp: Form 10-Q for the period ended Mar 30, 2024

- Company: [Plexus Corp](/companies/plxs.md) (CIK 785786)
- Form: 10-Q
- Filed: 2024-05-03
- Accepted by EDGAR: May 3, 2024, 12:06 ET
- Period: 2024-03-30
- Accession: 0000785786-24-000033
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/785786/000078578624000033/plxs-20240330.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/785786/000078578624000033/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-03-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-12-31 to 2024-03-30 | $997.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2023-10-01 to 2024-03-30 | $2.01bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-12-31 to 2024-03-30 | $878.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2023-10-01 to 2024-03-30 | $1.77bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-12-31 to 2024-03-30 | $88.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2023-10-01 to 2024-03-30 | $176.2m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2023-12-31 to 2024-03-30 | $47.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2023-10-01 to 2024-03-30 | $90.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-12-31 to 2024-03-30 | $29.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-10-01 to 2024-03-30 | $74.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-12-31 to 2024-03-30 | $8.3m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2023-10-01 to 2024-03-30 | $15.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-12-31 to 2024-03-30 | $2.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2023-10-01 to 2024-03-30 | $8.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-12-31 to 2024-03-30 | $16.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-10-01 to 2024-03-30 | $45.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-12-31 to 2024-03-30 | $0.58 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-10-01 to 2024-03-30 | $1.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-12-31 to 2024-03-30 | $0.59 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-10-01 to 2024-03-30 | $1.65 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-12-31 to 2024-03-30 | 27,929,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-10-01 to 2024-03-30 | 27,982,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-10-01 to 2024-03-30 | $84.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-10-01 to 2024-03-30 | $51.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2023-10-01 to 2024-03-30 | $17.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-03-30 | $265.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-03-30 | $2.63bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-03-30 | $3.28bn | us-gaap:Assets |
| Current liabilities | at 2024-03-30 | $1.74bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-03-30 | $2.02bn | us-gaap:Liabilities |
| Shareholders' equity | at 2024-03-30 | $1.26bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 43,292 characters.

### "SAFE HARBOR" CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

The statements contained in this Form 10-Q that are guidance or which are not historical facts (such as statements in the future tense and statements including believe, expect, intend, plan, anticipate, goal, target and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include the ability to realize anticipated savings from restructuring or similar actions, as well as the adequacy of related charges as compared to actual expenses; the effect of inflationary pressures on our costs of production, profitability, and on the economic outlook of our markets; the effects of shortages and delays in obtaining components as a result of economic cycles, natural disasters or otherwise; the risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs; the lack of visibility of future orders, particularly in view of changing economic conditions; the economic performance of the industries, sectors and customers we serve; the outcome of litigation and regulatory investigations and proceedings, including the results of any challenges with regard to such outcomes; the effects of tariffs, trade disputes, trade agreements and other trade protection measures; the effects of the volume of revenue from certain sectors or programs on our margins in particular periods; our ability to secure new customers, maintain our current customer base and deliver product on a timely basis; the risks of concentration of work for certain customers; the particular risks relative to new or recent customers, programs or services, which risks include customer and other delays, start-up costs, potential inability to execute, the establishment of appropriate terms of agreements, and the lack of a track record of order volume and timing; the effects of start-up costs of new programs and facilities or the costs associated with the closure or consolidation of facilities; possible unexpected costs and operating disruption in transitioning programs, including transitions between Company facilities; the risk that new program wins and/or customer demand may not result in the expected revenue or profitability; the fact that customer orders may not lead to long-term relationships; our ability to manage successfully and execute a complex business model characterized by high product mix and demanding quality, regulatory, and other requirements; the risks associated with excess and obsolete inventory, including the risk that inventory purchased on behalf of our customers may not be consumed or otherwise paid for by the customer, resulting in an inventory write-off; risks related to information technology systems and data security; increasing regulatory and compliance requirements; any tax law changes and related foreign jurisdiction tax developments; current or potential future barriers to the repatriation of funds that are currently held outside of the United States as a result of actions taken by other countries or otherwise; the potential effects of jurisdictional results on our taxes, tax rates, and our ability to use deferred tax assets and net operating losses; the weakness of areas of the global economy; the effect of changes in the pricing and margins of products; raw materials and component cost fluctuations; the potential effect of fluctuations in the value of the currencies in which we transact business; the effects of changes in economic conditions, political conditions and tax matters in the United States and in the other countries in which we do business; the potential effect of other world or local events or other events outside our control (such as the conflict between Russia and Ukraine, conflict in the Middle East, escalating tensions between China and Taiwan or China and the United States, changes in energy prices, terrorism, global health epidemics and weather events); the impact of increased competition; an inability to successfully manage human capital; changes in financial accounting standards; and other risks detailed herein and in our other Securities and Exchange Commission filings, particularly in Risk Factors contained in our fiscal 2023 Form 10-K.

### OVERVIEW

Plexus Corp. and its subsidiaries (together "Plexus," the "Company", "our", or "we") participate in the Electronic Manufacturing Services ("EMS") industry. Since 1979, we have been partnering with companies to create the products that build a better world. We are a global leader with a team of over 20,000 individuals who are dedicated to providing Design and Development, Supply Chain Solutions, New Product Introduction, Manufacturing and Sustaining Services. We specialize in serving customers in industries with highly complex products and demanding regulatory environments. We deliver customer service excellence to leading global companies in the Healthcare/Life Sciences, Industrial and Aerospace/Defense market sectors by providing innovative, comprehensive solutions throughout the product's lifecycle. We provide these innovative solutions to customers in the Americas ("AMER"), Asia-Pacific ("APAC") and Europe, Middle East and Africa ("EMEA") regions.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide an analysis of both short-term results and future prospects from management’s perspective, including an assessment of the financial condition and results of operations, events and uncertainties that are not indicative of future operations and any other financial or statistical data that we believe will enhance the understanding of our company’s financial condition, cash flows and other changes in financial condition and results of operations

The following information should be read in conjunction with our condensed consolidated financial statements included herein and "Risk Factors" included in Part II, Item 1A included herein as well as Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, and our "Safe Harbor" Cautionary Statement included above.

#### Market Pressures Update

During the first six months of fiscal 2024, we experienced market-driven inventory corrections at our customers and incrementally weaker demand from the Healthcare/Lifesciences and Industrial market sectors creating inefficiencies within our operations. We expect the market-driven inventory corrections at the customers and weaker demand in certain sectors to be a near-term challenge that will lessen later in fiscal 2024. However, if market softness continues for extended periods, this would impact our operating results in future periods.

A global minimum tax has been, or is anticipated to be, implemented in many of the countries in which we operate. We anticipate this will materially and unfavorably impact our existing tax holidays and effective tax rate beginning in our fiscal 2025. We will continue to monitor these developments as each jurisdiction incorporates such changes into tax laws.

We believe our balance sheet is positioned to support the potential future challenges presented by the macro-economic pressures we are facing. As of the second quarter of fiscal 2024, cash and cash equivalents and restricted cash were $265 million, while debt, finance lease obligations and other financing were $438 million. Borrowings under our Credit Facility as of March 30, 2024, were $239 million, leaving $261 million of our revolving commitment of $500 million available for use as well as the ability to expand our revolving commitment to $750 million upon mutual agreement with the bank. Interest expense could increase above current levels due to increased borrowing under our Credit Facility associated with working capital investments along with the impact of rising interest rates. Refer to Note 3, "Debt, Finance Lease and Other Financing Obligations," in Notes to Condensed Consolidated Financial Statements and "Management’s Discussion and Analysis Liquidity and Capital Resources" in Part I, Item 2 for further information.

### RESULTS OF OPERATIONS

***Consolidated Performance Summary.*** The following table presents selected consolidated financial data (dollars in millions, except per share data):

|  | Three Months Ended March 30, 2024 | April 1, 2023 | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $966.9 | $1,070.8 | $1,949.5 | $2,164.7 |
| Cost of sales | 878.8 | 967.8 | 1,773.3 | 1,960.6 |
| Gross profit | 88.1 | 103.0 | 176.2 | 204.2 |
| Gross margin | 9.1% | 9.6% | 9.0% | 9.4% |
| Operating income | 29.5 | 56.9 | 74.6 | 114.3 |
| Operating margin | 3.0% | 5.3% | 3.8% | 5.3% |
| Other expense | 10.5 | 9.1 | 20.8 | 17.0 |
| Income tax expense | 2.7 | 7.0 | 8.4 | 14.2 |
| Net income | 16.2 | 40.8 | 45.5 | 83.0 |
| Diluted earnings per share | $0.58 | $1.45 | $1.62 | $2.94 |
| Return on invested capital\* |  |  | 9.9% | 13.8% |
| Economic return\* |  |  | 1.7% | 4.8% |
| \*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below and Exhibit 99.1 for more information. |  |  |  |  |

***Net sales.*** For the three months ended March 30, 2024, net sales decreased $103.9 million, or 9.7%, as compared to the three months ended April 1, 2023. For the six months ended March 30, 2024, net sales decreased $215.2 million, or 9.9%, as compared to the six months ended April 1, 2023.

Net sales are analyzed by management by geographic segment, which reflects our reportable segments, and by market sector. Management measures operational performance and allocates resources on a geographic segment basis. Our global business development strategy is based on our targeted market sectors.

A discussion of net sales by reportable segment is presented below (in millions):

| Net sales: | Three Months Ended March 30, 2024 | April 1, 2023 | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: | ---: | ---: |
| AMER | $321.8 | $407.8 | $655.5 | $797.5 |
| APAC | 521.0 | 587.3 | 1,073.5 | 1,229.2 |
| EMEA | 154.8 | 101.8 | 276.7 | 191.2 |
| Elimination of inter-segment sales | (30.7) | (26.1) | (56.2) | (53.2) |
| Total net sales | $966.9 | $1,070.8 | $1,949.5 | $2,164.7 |

***AMER.*** Net sales for the three months ended March 30, 2024 in the AMER segment decreased $86.0 million, or 21.1%, as compared to the three months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers, as well as reductions in inflated component pricing. The decrease was further driven by a decrease of $14.5 million due to disengagements with customers and $9.3 million due to the discontinuation of a program with an existing customer. The decrease was partially offset by an increase of $12.3 million due to production ramps for new customers and $9.7 million due to production ramps of new products for existing customers.

During the six months ended March 30, 2024, net sales in the AMER segment decreased $142.0 million, or 17.8%, as compared to the six months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers, as well as reductions in inflated component pricing. The decrease was further driven by a decrease of $15.0 million due to disengagements with customers and $8.5 million due to the discontinuation of a program with an existing customer. The decrease was partially offset by an increase of $22.1 million due to production ramps for new customers.

***APAC.*** Net sales for the three months ended March 30, 2024 in the APAC segment decreased $66.3 million, or 11.3%, as compared to the three months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers, as well as reductions in inflated component pricing. The decrease was partially offset by a $7.9 million increase due to production ramps of new products for existing customers.

During the six months ended March 30, 2024, net sales in the APAC segment decreased $155.7 million, or 12.7%, as compared to the six months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers, as well as reductions in inflated component pricing. The decrease was further driven by a decrease of $29.5 million for end-of-life products. The decrease was partially offset by a $26.7 million increase due to production ramps of new products for existing customers.

***EMEA.*** Net sales for the three months ended March 30, 2024 in the EMEA segment increased $53.0 million, or 52.1%, as compared to the three months ended April 1, 2023. The increase in net sales was driven by a $39.6 million increase due to production ramps for new customers and overall net increased customer end-market demand. The increase was partially offset by a $5.9 million decrease due to the discontinuation of a program with an existing customer and reductions in inflated component pricing.

During the six months ended March 30, 2024, net sales in the EMEA segment increased $85.5 million, or 44.7%, as compared to the six months ended April 1, 2023. The increase in net sales was driven by a $59.1 million increase due to production ramps for new customers and overall net increased customer end-market demand. The increase was further driven by a $10.0 million increase in production ramps of new products for existing customers, partially offset by a $9.5 million decrease due to the discontinuation of a program with an existing customer and reductions in inflated component pricing.

Our net sales by market sector were as follows (in millions):

| Net sales: | Three Months Ended March 30, 2024 | April 1, 2023 | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: | ---: | ---: |
| Healthcare/Life Sciences | $378.4 | $487.3 | $759.3 | $975.2 |
| Industrial | 418.2 | 439.3 | 852.8 | 911.4 |
| Aerospace/Defense | 170.3 | 144.2 | 337.4 | 278.1 |
| Total net sales | $966.9 | $1,070.8 | $1,949.5 | $2,164.7 |

***Healthcare/Life Sciences.*** Net sales for the three months ended March 30, 2024 in the Healthcare/Life Sciences sector decreased $108.9 million, or 22.3%, as compared to the three months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers, as well as a reduction in inflated component pricing. The decrease was partially offset by an increase of $17.0 million due to production ramps of new products for existing customers.

During the six months ended March 30, 2024, net sales in the Healthcare/Life Sciences sector decreased $215.9 million, or 22.1%, as compared to the six months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers, as well as a reduction in inflated component pricing. The decrease was further driven by a decrease of $26.4 million for end-of-life products. The decrease was partially offset by an increase of $16.4 million due to production ramps of new products for existing customers and $6.0 million due to production ramps for a new customer.

***Industrial.*** Net sales for the three months ended March 30, 2024 in the Industrial sector decreased $21.1 million, or 4.8%, as compared to the three months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers as well as reductions in inflated component pricing. The decrease was further driven by a decrease of $16.4 million due to the discontinuation of programs with existing customers. The decrease was partially offset by an increase of $36.9 million due to production ramps for a new customer.

During the six months ended March 30, 2024, net sales in the Industrial sector decreased $58.6 million, or 6.4%, as compared to the six months ended April 1, 2023. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers as well as reductions in inflated component pricing.

The decrease was further driven by a decrease of $17.9 million due to the discontinuation of programs with existing customers and $7.7 million due to a disengagement with a customer. The decrease was partially offset by an increase of $62.0 million due to production ramps for new customers.

***Aerospace/Defense.*** Net sales for the three months ended March 30, 2024 in the Aerospace/Defense sector increased $26.1 million, or 18.1%, as compared to the three months ended April 1, 2023. The increase was driven by overall net increased customer end-market demand and an $11.2 million increase due to production ramps for new customers. The increase was partially offset by a reduction in inflated component pricing and a decrease of $10.9 million due to disengagements with customers.

During the six months ended March 30, 2024, net sales in the Aerospace/Defense sector increased $59.3 million, or 21.3%, as compared to the six months ended April 1, 2023. The increase was driven by overall net increased customer end-market demand, a $24.1 million increase due to production ramps of new products for existing customers and a $14.6 million increase due to production ramps for new customers. The increase was partially offset by a reduction in inflated component pricing and a decrease of $12.1 million due to disengagement with a customer.

***Cost of sales.*** Cost of sales for the three months ended March 30, 2024 decreased $89.0 million, or 9.2%, as compared to the three months ended April 1, 2023, while cost of sales for the six months ended March 30, 2024 decreased $187.3 million, or 9.6% as compared to the six months ended April 1, 2023. Cost of sales is comprised primarily of material and component costs, labor costs and overhead. For both the three and six months ended March 30, 2024 and April 1, 2023, approximately 89% of the total cost of sales was variable in nature and fluctuated with sales volumes. Approximately 88% of these costs were related to material and component costs.

As compared to the three months ended April 1, 2023, the decrease in cost of sales for the three months ended March 30, 2024 was primarily driven by the decrease in net sales and a positive shift in customer mix. As compared to the six months ended April 1, 2023, the decrease in cost of sales for the six months ended March 30, 2024 was primarily driven by the decrease in net sales and a positive shift in customer mix, partially offset by an increase in fixed costs.

***Gross profit.*** Gross profit for the three months ended March 30, 2024 decreased $14.9 million, or 14.5%, as compared to the three months ended April 1, 2023. Gross margin of 9.1% for the three months ended March 30, 2024 decreased 50 basis points compared to the three months ended April 1, 2023. The primary drivers of the decrease in gross profit and gross margin as compared to the three months ended April 1, 2023 were the decrease in net sales, partially offset by a positive shift in customer mix.

Gross profit for the six months ended March 30, 2024 decreased $28.0 million, or 13.7%, as compared to the six months ended April 1, 2023. Gross margin of 9.0% for the six months ended March 30, 2024 decreased 40 basis points compared to the six months ended April 1, 2023. The primary drivers of the decrease in gross profit and gross margin as compared to the six months ended April 1, 2023 were the decrease in net sales and an increase in fixed costs to support new customer program ramps, partially offset by a positive shift in customer mix.

***Operating income.*** Operating income for the three months ended March 30, 2024 decreased $27.4 million, or 48.2%, as compared to the three months ended April 1, 2023. Operating margin of 3.0% for the three months ended March 30, 2024 decreased 230 basis points compared to the three months ended April 1, 2023. The primary driver of the decrease in operating income and operating margin for the three months ended March 30, 2024 was the result of the decrease in gross margin as well as restructuring and other charges of $11.0 million. The restructuring and other charges consisted of severance from the reduction of the Company's workforce as well as closure costs associated with a site in the Company's EMEA region, offset by insurance proceeds received associated with an arbitration decision regarding a contractual matter that occurred in the Company's EMEA region in fiscal 2023.

Operating income for the six months ended March 30, 2024 decreased $39.7 million, or 34.7%, as compared to the six months ended April 1, 2023. Operating margin of 3.8% for the six months ended March 30, 2024 decreased 150 basis points compared to the six months ended April 1, 2023. The primary driver of the decrease in operating income and operating margin for the six months ended March 30, 2024 was the result of the decrease in gross margin as well as restructuring and other charges of $11.0 million, which consisted of employee severance costs associated with a reduction in the Company's workforce as well as closure costs associated with a site in the Company's EMEA region, offset by insurance proceeds received in an arbitration decision regarding a contractual matter that took place in the Company's EMEA region in fiscal 2023.

A discussion of operating income by reportable segment for the indicated fiscal period (in millions):

| Operating income: | Three Months Ended March 30, 2024 | April 1, 2023 | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: | ---: | ---: |
| AMER | $5.0 | $25.8 | $13.7 | $43.2 |
| APAC | 67.2 | 69.7 | 138.6 | 148.1 |
| EMEA | 5.7 | 1.8 | 5.5 | 1.2 |
| Corporate and other costs | (48.4) | (40.4) | (83.2) | (78.2) |
| Total operating income | $29.5 | $56.9 | $74.6 | $114.3 |

***AMER.*** Operating income decreased $20.8 million for the three months ended March 30, 2024 as compared to the three months ended April 1, 2023 primarily as a result of a decrease in net sales and a negative shift in customer mix, partially offset by a decrease in fixed costs.

During the six months ended March 30, 2024, operating income in the AMER segment decreased $29.5 million as compared to the six months ended April 1, 2023 primarily as a result of a decrease in net sales, partially offset by a positive shift in customer mix and a decrease in fixed costs.

***APAC.*** Operating income decreased $2.5 million for the three months ended March 30, 2024 as compared to the three months ended April 1, 2023 primarily as a result of a decrease in net sales, partially offset by a positive shift in customer mix.

During the six months ended March 30, 2024, operating income in the APAC segment decreased $9.5 million as compared to the six months ended April 1, 2023 primarily as a result of a decrease in net sales, partially offset by a positive shift in customer mix and a decrease in S&A.

***EMEA.*** Operating income increased $3.9 million for the three months ended March 30, 2024 as compared to the three months ended April 1, 2023 primarily as a result of an increase in net sales, partially offset by increased fixed costs.

During the six months ended March 30, 2024, operating income in the EMEA segment increased $4.3 million as compared to the six months ended April 1, 2023 primarily as a result of an increase in net sales, partially offset by increased fixed costs.

***Other expense.*** Other expense for the three months ended March 30, 2024 increased $1.4 million as compared to the three months ended April 1, 2023. The increase in other expense for the three months ended March 30, 2024 was primarily driven by a decrease in other miscellaneous income of $1.5 million.

Other expense for the six months ended March 30, 2024 increased $3.8 million as compared to the six months ended April 1, 2023. The increase in other expense for the six months ended March 30, 2024 was primarily driven by a decrease in other miscellaneous income of $2.5 million, an increase in interest expense of $0.7 million due to a higher average interest rate and an increase in factoring fees of $0.5 million.

***Income taxes.*** Income tax expense for the three and six months ended March 30, 2024 was $2.7 million and $8.4 million, respectively, compared to $7.0 million and $14.2 million for the three and six months ended April 1, 2023. The decrease is primarily due to a decrease in pre-tax book income.

Our annual effective tax rate varies from the U.S. statutory rate of 21.0% primarily due to the geographic distribution of worldwide earnings as well as a tax holiday granted to a subsidiary located in the APAC segment where we derive a significant portion of our earnings. Our effective tax rate may also be impacted by disputes with taxing authorities, tax planning activities, adjustments to uncertain tax positions and changes in valuation allowances.

The annual effective tax rate for fiscal 2024 is expected to be approximately 15.0% to 17.0% assuming no changes to tax laws.

***Net Income.*** Net income for the three months ended March 30, 2024 decreased $24.6 million, or 60.3%, from the three months ended April 1, 2023 to $16.2 million. Net income decreased primarily as a result of the decrease in operating income and the increase in other expense, partially offset by the decrease in tax expense as previously discussed.

Net income for the six months ended March 30, 2024 decreased $37.5 million, or 45.2%, from the six months ended April 1, 2023 to $45.5 million. Net income decreased primarily as a result of the decrease in operating income and the increase in other expense, partially offset by the decrease in tax expense as previously discussed.

***Diluted earnings per share.*** Diluted earnings per share decreased to $0.58 for the three months ended March 30, 2024 from $1.45 for the three months ended April 1, 2023 primarily as a result of decreased net income due to the factors discussed above, partially offset by a reduction in diluted shares outstanding.

Diluted earnings per share decreased to $1.62 for the six months ended March 30, 2024 from $2.94 for the six months ended April 1, 2023 primarily as a result of decreased net income due to the factors discussed above, partially offset by a reduction in diluted shares outstanding.

***Return on Invested Capital ("ROIC") and economic return.*** We use a financial model that is aligned with our business strategy and includes an ROIC goal of 15% which would exceed our weighted average cost of capital ("WACC") by more than 500 basis points and represent positive economic return. Economic return is the amount our ROIC exceeds our WACC.

Non-GAAP financial measures, including ROIC and economic return, are used for internal management goals and decision making because such measures provide management and investors additional insight into financial performance. In particular, we provide ROIC and economic return because we believe they offer insight into the metrics that are driving management decisions. We view ROIC and economic return as important measures in evaluating the efficiency and effectiveness of our long-term capital investments. We also use ROIC as a performance criteria in determining certain elements of compensation as well as economic return performance.

We define ROIC as tax-effected operating income before restructuring and other charges divided by average invested capital over a rolling three-quarter period for the second period. Invested capital is defined as equity plus debt and operating lease liabilities, less cash and cash equivalents. Other companies may not define or calculate ROIC in the same way. ROIC and other non-GAAP financial measures should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

We review our internal calculation of WACC annually. Our WACC is 8.2% for fiscal 2024 and 9.0% for fiscal 2023. By exercising discipline to generate ROIC in excess of our WACC, our goal is to create value for our shareholders. For the six months ended March 30, 2024, ROIC of 9.9% reflects an economic return of 1.7%, based on our WACC of 8.2%, and for the six months ended April 1, 2023, ROIC of 13.8% reflects an economic return of 4.8%, based on our weighted average cost of capital of 9.0%.

For a reconciliation of ROIC, economic return and adjusted operating income (tax-effected) to our financial statements that were prepared using U.S. GAAP, see Exhibit 99.1 to this quarterly report on Form 10-Q, which exhibit is incorporated herein by reference.

Refer to the table below, which includes the calculation of ROIC and economic return for the indicated fiscal period (dollars in millions):

|  | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: |
| Adjusted operating income (tax-effected) | $145.6 | $194.3 |
| Average invested capital | 1,478.1 | 1,406.4 |
| After-tax ROIC | 9.9% | 13.8% |
| WACC | 8.2% | 9.0% |
| Economic return | 1.7% | 4.8% |

26

### LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents and restricted cash were $265.1 million as of March 30, 2024 as compared to $256.7 million as of September 30, 2023.

As of March 30, 2024, 93% of our cash and cash equivalents balance was held outside of the U.S. by our foreign subsidiaries. Currently, we believe that our cash balance, together with cash available under our Credit Facility, will be sufficient to meet our liquidity needs and potential share repurchases for the next twelve months and the foreseeable future.

Our future cash flows from operating activities will be reduced by $31.4 million due to cash payments for U.S. federal taxes on the deemed repatriation of undistributed foreign earnings that are payable over an eight year period that began in fiscal 2019 with the first payment. The table below provides the expected timing of these future cash outflows, in accordance with the following installment schedule for the remaining two years (in millions):

|  |  |
| --- | ---: |
| 2025 | $14.2 |
| 2026 | 17.2 |
| Total | $31.4 |

***Cash Flows.*** The following table provides a summary of cash flows (in millions):

|  | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: |
| Cash flows provided by operating activities | $84.8 | $57.2 |
| Cash flows used in investing activities | (51.3) | (47.6) |
| Cash flows used in financing activities | (25.6) | (18.4) |
| Effect of exchange rate changes on cash and cash equivalents | 0.5 | 3.8 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | $8.4 | $(5.1) |

***Operating Activities.*** Cash flows provided by operating activities were $84.8 million for the six months ended March 30, 2024, as compared to cash flows provided by operating activities of $57.2 million for the six months ended April 1, 2023. The increase was primarily due to cash flow improvements (reductions) of:

- $(37.5) million decrease in net income.
- $81.8 million in inventory cash flows driven by a decrease in inventory in the six months ended March 30, 2024 compared to an increase in inventory in the six months ended April 1, 2023 due to inventory reduction efforts and fewer program ramps requiring upfront inventory procurement.
- $81.4 million in accounts payables cash flows primarily driven by the timing of materials procurement and payments to suppliers.
- $(66.3) million in accounts receivable cash flows driven by timing of shipments, mix of customer payment terms, partially offset by increased factoring of receivables.
- $(22.5) million in advanced payments from customers cash flows driven by a decrease in advanced payments in the six months ended March 30, 2024 compared to an increase in advanced payments in the six months ended April 1, 2023.
- $(16.5) million in other current and non-current asset cash flows driven by an increase in tax prepayments related to timing of payments and a larger increase in prepayments to suppliers in the six months ended March 30, 2024 compared to the six months ended April 1, 2023.

The following table provides a summary of cash cycle days for the periods indicated (in days):

|  | Three Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: |
| Days in accounts receivable | 61 | 56 |
| Days in contract assets | 12 | 11 |
| Days in inventory | 158 | 156 |
| Days in accounts payable | (65) | (69) |
| Days in advanced payments (1) | (75) | (72) |
| Annualized cash cycle | 91 | 82 |
| (1) Includes a reclassification in the presentation of advanced payments from customers reflected in prior period amounts. As of April 1, 2023, the impact of this reclassification was an increase in the Company's days in advanced payments and a reduction in annualized cash cycle by 22 days. |  |  |

We calculate days in accounts receivable and contract assets as each balance sheet item for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory, accounts payable and advanced payments as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate annualized cash cycle as the sum of days in accounts receivable, days in contract assets and days in inventory, less days in accounts payable and days in advanced payments.

As of March 30, 2024, annualized cash cycle days increased nine days compared to April 1, 2023 due to the following:

Days in accounts receivable for the three months ended March 30, 2024 increased five days compared to the three months ended April 1, 2023. The increase is attributable to the timing of customer shipments and payments, the mix of customer payment terms, as well as decreased factoring of receivables.

Days in contract assets for the three months ended March 30, 2024 increased one day compared to the three months ended April 1, 2023. The increase is primarily attributable to a decrease in advanced payments from customers with arrangements requiring revenue to be recognized over time as products are produced.

Days in inventory for the three months ended March 30, 2024 increased two days compared to the three months ended April 1, 2023. The increase is primarily due to lower sales in the three months ended March 30, 2024 compared to the prior year, partially offset by lower inventory.

Days in accounts payable for the three months ended March 30, 2024 decreased four days compared to the three months ended April 1, 2023. The decrease is primarily attributable to timing of materials procurement and payments to suppliers.

Days in advanced payments for the three months ended March 30, 2024 increased three days compared to the three months ended April 1, 2023. The increase was primarily attributable to lower sales in the three months ended March 30, 2024 compared to the prior year, partially offset by a decrease in advanced payments received from customers in line with lower inventory balances.

***Free Cash Flow.*** We define free cash flow ("FCF"), a non-GAAP financial measure, as cash flow generated or used in operations less capital expenditures. FCF was $33.3 million for the six months ended March 30, 2024 compared to $7.7 million for the six months ended April 1, 2023, an improvement of $25.6 million. The improvement in FCF was primarily due to lower working capital investments in inventory to support our customers and favorable accounts payable activity due to timing of payments.

Non-GAAP financial measures, including FCF, are used for internal management assessments because such measures provide additional insight to investors into ongoing financial performance. In particular, we provide FCF because we believe it offers insight into the metrics that are driving management decisions. We view FCF as an important financial metric as it demonstrates our ability to generate cash and can allow us to pursue opportunities that enhance shareholder value. FCF is a non-GAAP financial measure that should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with GAAP.

A reconciliation of FCF to our financial statements that were prepared using GAAP as follows (in millions):

|  | Six Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: |
| Cash flows provided by operating activities | $84.8 | $57.2 |
| Payments for property, plant and equipment | (51.5) | (49.5) |
| Free cash flow | $33.3 | $7.7 |

***Investing Activities.*** Cash flows used in investing activities were $51.3 million for the six months ended March 30, 2024 compared to $47.6 million for the six months ended April 1, 2023. The increase in cash used in investing activities was due to a $2.0 million increase in capital expenditures.

We estimate capital expenditures for fiscal 2024 will be approximately $100.0 million to $120.0 million to support new program ramps and replace older equipment.

***Financing Activities.*** Cash flows used in financing activities were $25.6 million for the six months ended March 30, 2024 compared to cash flows used in financing activities of $18.4 million for the six months ended April 1, 2023. The increase was primarily attributable to net borrowings on the credit facility for the six months ended March 30, 2024 of $6.0 million compared to net borrowings on the credit facility for the six months ended April 1, 2023 of $21.0 million, partially offset by a $6.3 million reduction in repurchases of our common stock.

On August 18, 2022, the Board of Directors approved a share repurchase program under which we are authorized to repurchase up to $50.0 million of its common stock (the "2023 Program"). The 2023 Program was completed in February 2024. During the three and six months ended March 30, 2024 we repurchased 59,277 shares under this program for $5.7 million at an average price of $95.59 per share. During the three months ended April 1, 2023, we repurchased 125,639 shares under this program for $12.4 million at an average price of $98.75 per share. During the six months ended April 1, 2023, we repurchased 241,362 shares under this program for $23.9 million at an average price of $98.93 per share.

On January 16, 2024, we announced an additional $50.0 million in share repurchase authority (the "2024 Program") that authorizes us to repurchase our common stock. The 2024 Program became effective upon completion of the 2023 Program, which occurred in February 2024, and has no expiration. During the three and six months ended March 30, 2024, we repurchased 126,850 shares under this program for $11.9 million at an average price of $93.83 per share. As of March 30, 2024, $38.1 million of the 2024 Program remained available to repurchase shares.

All shares repurchased under the aforementioned programs were recorded as treasury stock.

We have Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which we may elect to sell receivables, at a discount. These facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of March 30, 2024 is $340.0 million. The maximum facility amount under the HSBC RPA as of March 30, 2024 is $70.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

We sold $213.8 million and $225.7 million of trade accounts receivable under these programs during the three months ended March 30, 2024 and April 1, 2023, respectively, in exchange for cash proceeds of $211.1 million and $222.9 million, respectively. We sold $437.4 million and $411.3 million of trade accounts receivable under these programs during the six months ended March 30, 2024 and April 1, 2023, respectively, in exchange for cash proceeds of $432.1 million and $406.5 million, respectively. As of March 30, 2024 and September 30, 2023, $217.8 million and $220.5 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by us remained outstanding and had not yet been collected by MUFG Bank or HSBC Bank.

In all cases, the sale discount was recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. For further information regarding the receivable sale programs, see Note 13, "Trade Accounts Receivable Sale Programs," in Notes to Condensed Consolidated Financial Statements.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execution upon our share repurchase authorizations as management deems appropriate, for the next twelve months. We believe our balance sheet is positioned to support the potential future challenges presented by macroeconomic factors including increased working capital requirements associated with longer lead-times for components, increased component and labor costs, and operating inefficiencies due to supply chain constraints. As of the end of the second quarter of fiscal 2024, cash and cash equivalents and restricted cash were $265 million, while debt, finance lease and other financing obligations were $438 million. If our future financing needs increase, then we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to make any such arrangements on acceptable terms or at all.

### DISCLOSURE ABOUT CRITICAL ACCOUNTING ESTIMATES

Our critical accounting policies are disclosed in our 2023 Annual Report on Form 10-K. During the second quarter of fiscal 2024, there were no material changes.

### NEW ACCOUNTING PRONOUNCEMENTS

See Note 1, "Recently Adopted Accounting Pronouncements" and "Recently Issued Accounting Pronouncements Not Yet Adopted," in Notes to Condensed Consolidated Financial Statements regarding recent accounting pronouncements.

## Market risk

As filed, 4,417 characters.

There were no material changes in our exposure to market risk from changes in foreign exchange and interest rates from those disclosed in our 2023 Annual Report on Form 10-K.

### Foreign Currency Risk

Our international operations create potential foreign exchange risk. Our policy is to selectively hedge our foreign currency denominated transactions in a manner that partially offsets the effects of changes in foreign currency exchange rates. We typically use foreign currency contracts to hedge only those currency exposures associated with certain assets and liabilities denominated in non-functional currencies. Corresponding gains and losses on the underlying transaction generally offset the gains and losses on these foreign currency hedges. We cannot predict changes in currency rates, nor the degree to which we will be able to manage the impacts of currency exchange rate changes. Such changes could have a material effect on our business, results of operations and financial condition.

Our percentages of transactions denominated in currencies other than the U.S. dollar for the indicated periods were as follows:

|  | Three Months Ended March 30, 2024 | April 1, 2023 |
| --- | ---: | ---: |
| Net Sales | 13% | 9% |
| Total Costs | 18% | 21% |

We have evaluated the potential foreign currency exchange rate risk on transactions denominated in currencies other than the U.S. dollar for the periods presented above. Based on our overall currency exposure, as of March 30, 2024, a 10.0% change in the value of the U.S. dollar relative to our other transactional currencies would not have a material effect on our financial position, results of operations, or cash flows.

### Interest Rate Risk

We have financial instruments, including cash equivalents and debt, which are sensitive to changes in interest rates. The primary objective of our investment activities is to preserve principal, while maximizing yields without significantly increasing market risk. To achieve this, we limit the amount of principal exposure to any one issuer.

As of March 30, 2024, we were exposed to interest rate risk associated with our Credit Facility. Borrowings under the Credit Facility bear interest, at the Company's option, at (a)(1) for borrowings denominated in U.S. dollars, the Term Secured Overnight Financing Rate ("SOFR"), (2) for borrowings denominated in pounds sterling, the Daily Simple Risk-Free Rate, plus, in each case of (a)(1) and (2), 10 basis points, (b) for borrowings denominated in euros, the EURIBOR Rate plus a statutory reserve rate, or (c) an Alternate Base Rate equal to the highest of (i) 100 basis points per annum, (ii) the prime rate last quoted by The Wall Street Journal (or, if not quoted, as otherwise provided in the Credit Facility), (iii) the greater of the federal funds effective rate and the overnight bank funding rate in effect on such day plus, in each case, 50 basis points per annum (or, if neither are available, as otherwise provided in the Credit Facility), and (iv) Term SOFR for a one month interest period on such day plus 110 basis points, plus, in each case of (a), (b), and (c), an applicable interest rate margin based on the Company's then current consolidated total indebtedness (minus certain unrestricted cash and cash equivalents in an amount not to exceed $100 million) to consolidated EBITDA. As of March 30, 2024, the borrowing rate under the Credit Facility was SOFR plus 1.10%. Borrowings under the 2018 NPA are based on a fixed interest rate, thus mitigating much of our interest rate risk. We were also exposed to interest rate risk on our accounts receivables sales programs. The Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (the "MUFG RPA") is subject to an applicable cost of funds based on an applicable margin defined in the agreement with respect to receivables owed by each approved obligor and the applicable SOFR for a period equal to the discount period applicable to such receivable determined as of two business days prior to the applicable purchase date of such receivable with respect to the currency the receivable is denominated in. Other trade receivable sales programs are subject to similar terms. Based on our overall interest rate exposure, as of March 30, 2024, a 10.0% change in interest rates would not have a material effect on our financial position, results of operations, or cash flows.

## Controls and procedures

As filed, 1,648 characters.

### Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to ensure that the information the Company must disclose in its filings with the Securities and Exchange Commission ("SEC") is recorded, processed, summarized and reported on a timely basis. The Company’s Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have reviewed and evaluated, with the participation of the Company’s management, the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report. Based on such evaluation, the CEO and CFO have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective, at the reasonable assurance level, (a) in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act, and (b) in assuring that information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

During the second quarter of fiscal 2024, there have been no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 406 characters.

In addition to the risks and uncertainties discussed herein, particularly those discussed in the “Safe Harbor” Cautionary Statement and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Part I, Item 2, see the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 that have had no material changes.

Filed May 3, 2024.
Source: SEC EDGAR, the filing index for accession 0000785786-24-000033. Last ingested by Listed: Oct 24, 2026, 14:56 ET. No prices; not investment advice.
